Wegovy sales smash forecasts after pill launch as Novo Nordisk hikes guidance

Novo Nordisk reported first-quarter sales of 96.8 billion Danish kroner, up 32% on a constant-currency basis and well above the 71.3 billion kroner consensus, while operating profit jumped 65% to 59.6 billion kroner versus expectations of 31.7 billion kroner. Wegovy pill sales reached 2.26 billion kroner in its first U.S. quarter, and the company said the launch delivered around 1.3 million prescriptions. Novo also raised its full-year outlook, though it now expects adjusted sales and operating profit growth to contract by 4% to 12% on a currency-adjusted basis.

Analysis

The key read-through is not just better execution, but a reset in the market’s perception of addressable demand: oral GLP-1s materially reduce the “needle barrier,” which expands the trial universe beyond existing injectables and should pull forward adoption among patients who were previously treatment-resistant. That matters for supply-chain and competitors because the growth ceiling is now less about brand awareness and more about manufacturing, payer access, and physician inertia; the first two are fixable with capital, while the last is slower to erode.

A second-order implication is that the category is becoming more resilient to individual molecule volatility. If oral and injectable demand are both scaling, then mix shifts can mute near-term expectations for the injectable franchise while still increasing total category profit pools. That makes near-term headline comparisons noisy, but it also raises the bar for bear cases built on “peak GLP-1” assumptions.

The main risk is sequencing: strong launch data can lull investors into extrapolating too aggressively before real-world persistence, refill rates, and payer authorization friction show up over the next 2-4 quarters. If discontinuation rates on the oral product normalize toward broader obesity-drug norms, the market may need to re-rate the growth durability of the category lower even if prescription counts stay elevated. Watch for any indication that promotional intensity or channel fill is doing more work than patient retention.

The consensus may be underestimating the competitive shock to smaller obesity names and adjacent services rather than just to direct pharma peers. A successful oral format should pressure telehealth distributors, cash-pay obesity clinics, and compounding ecosystems first, because they depend on access gaps and convenience premiums; those margins are now at risk if branded oral penetration accelerates faster than expected.

Key Decisions for Investors

• Maintain/expand long NVO on a 3-6 month horizon; use pullbacks after the post-print momentum fades. Risk/reward remains favorable as guidance has likely moved the market from skepticism to underappreciating duration, but expect volatility from any refill/persistence data.
• Pair trade: long NVO / short a basket of GLP-1-adjacent losers with weaker balance sheets or access models (e.g., telehealth/compounding exposure) for 1-3 quarters. The thesis is that branded oral adoption compresses the convenience premium and squeezes margin in the gray-market ecosystem.
• Consider a call spread on NVO 6-12 months out rather than outright stock if volatility is elevated. You want upside exposure to category expansion while capping premium paid if the market has already priced in near-term launch exuberance.
• Watch for a short opportunity in any competitor rally tied to ‘GLP-1 growth’ if they lack oral parity or manufacturing scale. The trade works best after strong sector sympathy moves, with a 1-2 month horizon, because the winner likely captures incremental demand while peers absorb multiple compression.
• Set a catalyst trigger around upcoming persistence/refill or payer data; if those are softer than prescription momentum, trim longs into strength. That is the key event that could reverse the current bullish narrative within 1-2 quarters.